Clinical trial · Interventional
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low enrollment through COVID pandemic
Summary
Brief summary (as posted)
Asbestos defines a group of naturally occurring mineral silicate fibers which are easily inhaled, resulting in a variety of diseases of the respiratory system including lung cancer and malignant mesothelioma. Despite some advances in treatment, there has been little impact on overall survival for both lung cancer and mesothelioma in the past 20 years in great part because patients usually present with disease at an advanced and incurable stage. This study aims to develop and implement a low-dose computed tomography (LDCT) screening approach for lung cancer and mesothelioma in asbestos-exposed workers in Alberta.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Mesothelioma | Malignant Mesothelioma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low-dose computed tomography Annual scan x3 | Procedure | — | UNRESOLVED |
| Low-dose computed tomography Baseline scan only | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- High lung cancer risk
- description
- Individuals with lung cancer risk \>= 1.5% over 6 years
- interventionNames
- Procedure: Low-dose computed tomography Annual scan x3
- type
- EXPERIMENTAL
- label
- Low lung cancer risk
- description
- Individuals with lung cancer risk \<1.5% over 6 years
- interventionNames
- Procedure: Low-dose computed tomography Baseline scan only
Primary outcomes (1)
- measure
- Change in SF-12 quality of life score
- timeFrame
- Baseline vs. 14 days post receipt of screen results.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age 50 - 80 years (either gender, any ethnic group) * Documented exposure to asbestos for at least one year, at least 10 years prior to study entry * Ability to provide informed consent and participate in study procedures Exclusion Criteria: * Any medical condition, such as severe heart disease (e.g. unstable angina, chronic congestive heart failure), severe lung disease or lung disease requiring supplemental oxygen, solid organ transplant, that in the opinion of the physician unlikely to benefit from screening due to shortened life-expectancy from the co-morbidities or inability to tolerate diagnosis and treatment of a screen detected abnormality * Have been previously diagnosed with lung cancer or mesothelioma * Have had other cancer within the past 5 years with the exception of the following cancers: non-melanomatous skin cancer, localized prostate cancer, carcinoma in situ (CIS) of the cervix, or superficial bladder cancer. Treatment of the exceptions must have ended \>6 months before registration into this study * Pregnancy * CT scan of the chest in the past 2 years * Unwilling to have a LDCT of chest * Unwilling to sign a consent
References
Publications (0)
Data not yet available